Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | PPARG | P37231 | 3/20 | 0.67 |
| ▸ | CPA1 | P15085 | 7/20 | 0.66 |
| ▸ | CPA3 | P15088 | 3/20 | 0.66 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.66 |
| ▸ | CPB1 | P15086 | 1/20 | 0.66 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.66 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491524 | 1.00 | CYP1A2 (0.83) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL265063 | 1.00 | CYP1A2 (0.83) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL4664822 | 0.91 | CYP1A2 (1.00) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL12493651 | 0.90 | CYP1A2 (0.74) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL22115491 | 0.89 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL27291058 | 0.89 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL9875948 | 0.89 | CYP1A2 (0.95) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL4886609 | 0.88 | CYP1A2 (0.69) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL21895912 | 0.86 | CYP1A2 (0.67) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL11634382 | 0.86 | CYP1A2 (0.67) | CYP1A2PPARGCPA1CPA3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-20240024410-A1 | THREE-DIMENTIONAL SURFACE FOR PROTEIN AND SMALL MOLECULE MICROARRAYS | THE JOHNS HOPKINS UNIVERSITY | 2024-01-25 | — | — | US | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180072784-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008002449-A2 | GLYCOMIMETIC INHIBITORS OF SIGLEC-8 | GLYCOMIMETICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1203770-B1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | UPJOHN CO (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-0668860-B1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | UPJOHN CO (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1203770-A1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-0668860-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | PHARMACIA & UPJOHN COMPANY (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072784-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, SERPINC1 | CYP1A2 4247/4885PPARG 4775/4885CPA1 82/4885 |
| US-11708391-B2 | Rapaglutins, novel inhibitors of GLUT and use thereof | SLC2A1, SLC2A4, SLC2A2 | CYP1A2 3807/4885PPARG 906/4885CPA1 3224/4885 |
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | CYP1A2 378/4885PPARG 2030/4885CPA1 2386/4885 |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | CYP1A2 1088/4885PPARG 509/4885CPA1 745/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | CYP1A2 4351/4885PPARG 4746/4885CPA1 81/4885 |
| US-20240024410-A1 | THREE-DIMENTIONAL SURFACE FOR PROTEIN AND SMALL MOLECULE MICROARRAYS | MRPS23, CD2BP2, MRPL21 | CYP1A2 4720/4885PPARG 4600/4885CPA1 2868/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | CYP1A2 378/4885PPARG 2030/4885CPA1 2386/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | CYP1A2 4346/4885PPARG 4779/4885CPA1 77/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CYP1A2 2147/4885PPARG 2451/4885CPA1 2108/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | CYP1A2 1009/4885PPARG 3056/4885CPA1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.